Literature DB >> 32901502

Immunologic phenotype of a child with the MEHMO syndrome.

I Trochanová1, D Staníková, M Škopková, K Haštová, D Gašperíková, J Staník, P Čižnár.   

Abstract

MEHMO syndrome is a rare X-linked syndrome characterized by Mental retardation, Epilepsy, Hypogenitalism, Microcephaly, and Obesity associated with the defect of protein synthesis caused by the EIF2S3 gene mutations. We hypothesized that the defect in protein synthesis could have an impact on the immune system. We describe immunologic phenotype and possible treatment outcomes in patient with MEHMO syndrome carrying a frame-shift mutation (I465fs) in the EIF2S3 gene. The proband (currently 9-year-old boy) had normal IgG and IgM levels, but had frequent respiratory and urinary tract infections. On subcutaneous immunoglobulin therapy achieving supra-physiological IgG levels the frequency of infections significantly decreased in Poisson regression by 54.5 % (CI 33.2-89.7, p=0.017). The MEHMO patient had had frequent acute infections despite normal IgG and IgM serum levels and responded well to the immunoglobulin treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32901502      PMCID: PMC8549901          DOI: 10.33549/physiolres.934498

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  13 in total

1.  Population prevalence of diagnosed primary immunodeficiency diseases in the United States.

Authors:  J M Boyle; R H Buckley
Journal:  J Clin Immunol       Date:  2007-06-19       Impact factor: 8.317

2.  MEHMO (mental retardation, epileptic seizures, hypogonadism and -genitalism, microcephaly, obesity), a novel syndrome: assignment of disease locus to xp21.1-p22.13.

Authors:  R Steinmüller; D Steinberger; U Müller
Journal:  Eur J Hum Genet       Date:  1998 May-Jun       Impact factor: 4.246

Review 3.  Immunity - a significant pathogenic factor as well as an integral part of the psychoneuroendocrine-immune regulations.

Authors:  F Vožeh
Journal:  Physiol Res       Date:  2018-01-05       Impact factor: 1.881

4.  Wolcott-Rallison syndrome due to the same mutation in EIF2AK3 (c.205G>T) in two unrelated families: A case report.

Authors:  Ai Huang; Haiyan Wei
Journal:  Exp Ther Med       Date:  2019-02-13       Impact factor: 2.447

5.  EIF2S3 Mutations Associated with Severe X-Linked Intellectual Disability Syndrome MEHMO.

Authors:  Martina Skopkova; Friederike Hennig; Byung-Sik Shin; Clesson E Turner; Daniela Stanikova; Katarina Brennerova; Juraj Stanik; Ute Fischer; Lyndal Henden; Ulrich Müller; Daniela Steinberger; Esther Leshinsky-Silver; Armand Bottani; Timea Kurdiova; Jozef Ukropec; Olga Nyitrayova; Miriam Kolnikova; Iwar Klimes; Guntram Borck; Melanie Bahlo; Stefan A Haas; Joo-Ran Kim; Leda E Lotspeich-Cole; Daniela Gasperikova; Thomas E Dever; Vera M Kalscheuer
Journal:  Hum Mutat       Date:  2017-01-23       Impact factor: 4.878

Review 6.  Wolcott-Rallison syndrome.

Authors:  Cécile Julier; Marc Nicolino
Journal:  Orphanet J Rare Dis       Date:  2010-11-04       Impact factor: 4.123

7.  Two novel EIF2S3 mutations associated with syndromic intellectual disability with severe microcephaly, growth retardation, and epilepsy.

Authors:  Stéphanie Moortgat; Julie Désir; Valérie Benoit; Sébastien Boulanger; Hélène Pendeville; Marie-Cécile Nassogne; Damien Lederer; Isabelle Maystadt
Journal:  Am J Med Genet A       Date:  2016-06-22       Impact factor: 2.802

8.  Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery.

Authors:  Vicki Modell; Megan Knaus; Fred Modell; Chaim Roifman; Jordan Orange; Luigi D Notarangelo
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

Review 9.  New insights into translational regulation in the endoplasmic reticulum unfolded protein response.

Authors:  Graham D Pavitt; David Ron
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

10.  Primary immunodeficiency.

Authors:  Christine McCusker; Richard Warrington
Journal:  Allergy Asthma Clin Immunol       Date:  2011-11-10       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.